Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — Investor Presentation (April 2022)
39 slides from Collegium Pharmaceutical's investor presentation, Apr 13, 2022
Slide 1: Corporate Presentation April 2022
April 2022 | Nasdaq: COLL Corporate Presentation Investor Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates,"
Slide 3: Building a leading, diversified specialty pharmaceutical company
Building a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions I D E A Uphold Integrity Embrace Differences Encourage Expression Be Accountable GUIDED BY OUR CORE VALUES Mission Driven Investor Presentation
Slide 4: Focused on Sustainability and Social Impact
Focused on Sustainability and Social Impact ENVIRONMENTAL Be a responsible steward of the environment • Transitioning Xtampza® ER to 2x scale manufacturing • Product packaging with recyclable materials • Hybrid work week • Single stream recycling and light automation at Headquarters • Offering hybri
Slide 5: Collegium Board of Directors and Management Team
Collegium Board of Directors Joseph Ciaffoni President & CEO, Collegium Pharmaceutical Michael Heffernan Chairman of the Board & Collegium Founder Garen Bohlin Former COO, Sirtris, Former CEO, Syntonix John Freund, M.D. Co-Founder & Partner, Skyline Ventures Gwen Melincoff Former Senior BD roles, BT
Slide 6: 2022 is a Pivotal Year
2022 is a Pivotal Year GROW TOP AND BOTTOM LINES Grow Xtampza ER and Belbuca® Maximize Nucynta® Franchise and Symproic® Launch Elyxyb™ Renegotiate Xtampza ER contracts INTEGRATE BDSI Seamless transition of core operations Achieve annual run rate synergies of at least $75 million DEPLOY CAPITAL Busin
Slide 7: BDSI Acquisition is Strategically and Financially Transformative
BDSI Acquisition is Strategically and Financially Transformative SCALES AND DIVERSIFIES REVENUE $441.5m pro forma 2021 net revenue1 EXPECT TO DELIVER >$75 MILLION IN ANNUAL RUN RATE SYNERGIES2 Launch Opportunity IMMEDIATELY AND HIGHLY ACCRETIVE2 FOOTHOLD IN NEUROLOGY Business Development Priority 1.
Slide 8: Collegium 3-Phase Action Agenda
Collegium 3-Phase Action Agenda PHASE 1 SEAMLESS INTEGRATION PHASE 2 GENERATE MOMENTUM PHASE 3 ACCELERATE 1. No disruptions to core operations 2. Day 1 commercial readiness 3. Achieve majority of >$75M target synergies 1. Grow Xtampza ER and Belbuca TRxs 2. Complete Xtampza ER contract renegotiation
Slide 9: Strong Financial Position
Strong Financial Position1,2 REVENUE GROWTH & SCALE $133M SIGNIFICANT COST LEVERAGE3 Est. 2022 Adj. EBITDA of $235-250M ~+105% y/y at mid-point 1. This financial data was provided by Collegium in its press release filed with the SEC on April 5, 2022. 2. Percent change year-over-year is calculated ba
Slide 10: Diverse and Durable Commercial Portfolio
Diverse and Durable Commercial Portfolio GROWTH DRIVERS CONTRIBUTORS LAUNCH OPPORTUNITY Sept 2033 Jan 2027 July 2025 Nov 2031 PROJECTED EXCLUSIVITY THROUGH… 2036 * Potential for pediatric extension to year-end 2025 Investor Presentation
Slide 11: The Leader in Responsible Pain Management
The Leader in Responsible Pain Management Sources: 1. IQVIA NPA, February 2022 2. ATU (Attitudes, Trial & Awareness) Market Research Study fielded Q1 2021 ACUTE CHRONIC PORTFOLIO SPANS THE CONTINUUM OF CARE Pain Portfolio distinctly positioned and sources differently Highly differentiated products t
Slide 12: Xtampza ER and Belbuca: Durable Growth Drivers
Xtampza ER and Belbuca: Durable Growth Drivers Sources: 1. IQVIA Monthly NPA through Feb 2022 2. IQVIA Exponent through Q4 2021 3. Symphony Metas data through Q4 2021 DURABLE ASSETS Exclusivity through at least September 2033 Exclusivity through at least January 2027 STRONG MARKET POSITION ~34% shar
Slide 13: A Strategic Foothold in Neurology
A Strategic Foothold in Neurology NEUROLOGY IS A TARGET ADJACENCY ELYXYB LAUNCH OPPORTUNITY • Focused and Phased Approach • Where we choose to play, we will play to win • Success gated expansion • Business Development Priority • Aligned to organizational capabilities • Complimentary to Pain Investor
Slide 14: Migraine Market Opportunity
Migraine Market Opportunity 39 million people suffer from migraines in the US1 LARGE & GROWING US MARKET >70% of patients report inadequate treatment response with acute migraine2 Acute migraine market dominated by Triptan Rxs (70% of prescriptions)3 CGRPs showing discontinuation at a high rate (~50
Slide 15: Maximizing the Value of Nucynta and Symproic as Key Contributors
Maximize profitability through contracting strategy ~70% of Nucynta Franchise prescriptions are covered by the pain salesforce3 Differentiated opioid with proposed dual mechanism of action1,2 Maximizing the Value of Nucynta and Symproic as Key Contributors Sources: 1. Nucynta Full Prescribing Inform
Slide 16: Capital Allocation Priorities
OPPORTUNISTICALLY RETURN CAPITAL TO SHAREHOLDERS RAPIDLY PAYDOWN DEBT FOCUSED BUSINESS DEVELOPMENT Capital Allocation Priorities • Commercial-stage neurology assets • ~$50M remaining on $100M share repurchase program2 • New $650M Pharmakon loan issued on 3/22/222 • $100M to be repaid in first 12 mon
Slide 17: Building a Leading, Diversified Specialty Pharmaceutical Company Through Acquisitions
BUSINESS DEVELOPMENT FOCUS • Commercial-stage neurology assets Building A Leading, Diversified Specialty Pharmaceutical Company Through Financially Transformative Acquisitions STRONG TRACK RECORD Nucynta Franchise (February 2020) BDSI (March 2022) Investor Presentation
Slide 18: 2022 Financial Guidance
2022 Financial Guidance1 1. This financial data was provided by Collegium in its press release filed with the SEC on April 5, 2022. 2. Adjusted EBITDA is a non-Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensa
Slide 19: Building a Leading, Diversified Specialty Pharmaceutical Company
Building a Leading, Diversified Specialty Pharmaceutical Company DIVERSE AND DURABLE PORTFOLIO STRONG FINANCIAL POSITION LONG-TERM VALUE CREATION Leadership in pain Foothold in neurology Xtampza ER exclusive to Sept. 2033, Belbuca exclusive to Jan. 2027 Revenue expected to grow ~65% YoY1 Significant
Slide 20: Important Safety Information
Important Safety Information Investor Presentation
Slide 21: Xtampza ER Important Safety Information
Important Safety Information about XTAMPZA ER (oxycodone) extended-release capsules WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTI
Slide 22: Xtampza ER Safety Information (continued)
Accidental Ingestion Accidental ingestion of even one dose of Xtampza ER, especially by children, can result in a fatal overdose of Oxycodone. Neonatal Opioid Withdrawal Syndrome Prolonged use of Xtampza ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threate
Slide 23: Belbuca Important Safety Information
Important Safety Information about BELBUCA (buprenorphine buccal film) WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODI
Slide 24: Belbuca Safety Information (continued)
Neonatal Opioid Withdrawal Syndrome Prolonged use of BELBUCA during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid wit
Slide 25: Nucynta ER Important Safety Information
Important Safety Information about NUCYNTA ER (tapentadol) extended-release tablets WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH ALCOHOL and
Slide 26: Nucynta ER Safety Information (continued)
Neonatal Opioid Withdrawal Syndrome Prolonged use of NUCYNTA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required
Slide 27: Nucynta Important Safety Information
Important Safety Information about NUCYNTA (Tapentadol) tablets WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPIN
Slide 28: Nucynta Safety Information (continued)
Neonatal Opioid Withdrawal Syndrome Prolonged use of NUCYNTA tablets during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is requ
Slide 29: Elyxyb Important Safety Information
Important Safety Information about ELYXYB (celecoxib) oral solution WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myoc
Slide 30: Elyxyb Contraindications, Warnings and Precautions
CONTRAINDICATIONS ELYXYBis contraindicated in the following patients: • Known hypersensitivity to celecoxib or any components of the drug product or sulfonamides • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs • In the setting of coronary artery
Slide 31: Elyxyb Warnings and Precautions (continued)
• Anaphylactic Reactions: Celecoxib has been associated with anaphylactic reactions in patients with and without known hypersensitivity to celecoxib and in patients with aspirin-sensitive asthma. Celecoxib is a sulfonamide and both NSAIDs and sulfonamides may cause allergic-type reactions including
Slide 32: Elyxyb Warnings and Adverse Reactions
• Masking of Inflammation and Fever: The pharmacological activity of celecoxib in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections. • Laboratory Monitoring: Because serious GI bleeding, hepatotoxicity, and renal injury can occur without
Slide 33: Elyxyb Use in Specific Populations
USE IN SPECIFIC POPULATIONS Infertility: NSAIDs are associated with reversible infertility. Consider withdrawal of ELYXYBTM in women who have difficulties conceiving. Pregnancy and Fetal/Neonatal Adverse Reactions Use of NSAIDs, including ELYXYB, can cause premature closure of the fetal ductus arter
Slide 34: Symproic Important Safety Information
Important Safety Information about SYMPROIC (naldemedine) tablets SYMPROIC may cause serious side effects, including: • Tear in your stomach or intestinal wall (perforation). Stomach pain that is severe can be a sign of a serious medical condition. If you get stomach pain that does not go away, stop
Slide 35: Symproic Indications and Usage
INDICATIONS AND USAGE SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. CONTRA
Slide 36: Symproic Use in Specific Populations
USE IN SPECIFIC POPULATIONS Pregnancy There are no available data with Naldemedine in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. There is a potential for opioid withdrawal in a fetus when SYMPROIC is used in pregnant women. SYMPROIC should be used during
Slide 37: Non-GAAP Reconciliations
Non-GAAP Reconciliations Investor Presentation
Slide 38: Reconciliation of GAAP Net Income to Adjusted EBITDA
Non-GAAP Reconciliations Collegium Pharmaceutical, Inc. Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands) (unaudited) GAAP net (loss) income $ (25,034) $ 6,958 $ 71,517 $ 26,752 Adjustments: Interest expense 4,757 7,737 21,014 28,882 Interest income (3) (3) (12) (232) Provision for
Slide 39: Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses
Non-GAAP Reconciliations Collegium Pharmaceutical, Inc. Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands) (unaudited) Investor Presentation
Collegium Pharmaceutical — Investor Presentation (April 2022) on 6ix